

Enrico Proietti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1927611/publications.pdf>

Version: 2024-02-01

65
papers

4,792
citations

147801

31
h-index

106344

65
g-index

67
all docs

67
docs citations

67
times ranked

7570
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer cellâ€™s autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	30.7	823
2	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmunology</i> , 2014, 3, e955691.	4.6	686
3	Interferon-alpha in tumor immunity and immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2002, 13, 119-134.	7.2	306
4	Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. <i>Cancer Research</i> , 2011, 71, 768-778.	0.9	304
5	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011, 33, 369-383.	6.1	265
6	Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration. <i>Clinical Cancer Research</i> , 2007, 13, 644-653.	7.0	228
7	Type I IFN as a Natural Adjuvant for a Protective Immune Response: Lessons from the Influenza Vaccine Model. <i>Journal of Immunology</i> , 2002, 169, 375-383.	0.8	208
8	Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. <i>Blood</i> , 2000, 95, 2024-2030.	1.4	189
9	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	4.4	139
10	Chemotherapy enhances vaccineâ€™induced antitumor immunity in melanoma patients. <i>International Journal of Cancer</i> , 2009, 124, 130-139.	5.1	103
11	Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. <i>Vaccine</i> , 2005, 23, 2994-3004.	3.8	88
12	Identification of Tissue-Restricted Transcripts in Human Islets. <i>Endocrinology</i> , 2004, 145, 4513-4521.	2.8	87
13	Type I IFN Protects Permissive Macrophages from <i>Legionella pneumophila</i> Infection through an IFN-Î³-Independent Pathway. <i>Journal of Immunology</i> , 2004, 173, 1266-1275.	0.8	77
14	Cyclophosphamide Induces a Type I Interferonâ€™Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 4249-4261.	7.0	73
15	APC Activation by IFN-Î± Decreases Regulatory T Cell and Enhances Th Cell Functions. <i>Journal of Immunology</i> , 2010, 184, 5969-5979.	0.8	72
16	Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. <i>Cancer Research</i> , 2011, 71, 3528-3539.	0.9	72
17	Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 169-178.	3.8	64
18	Type I Interferon Is a Powerful Inhibitor of in Vivo HIV-1 Infection and Preserves Human CD4+ T Cells from Virus-Induced Depletion in SCID Mice Transplanted with Human Cells. <i>Virology</i> , 1999, 263, 78-88.	2.4	57

#	ARTICLE	IF	CITATIONS
19	Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-specific, Tumor-Reactive CTL in Melanoma Patients. <i>Cancer Research</i> , 2010, 70, 7084-7092.	0.9	57
20	Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. <i>Molecular Oncology</i> , 2012, 6, 1-14.	4.6	48
21	Type I interferons as vaccine adjuvants against infectious diseases and cancer. <i>Expert Review of Vaccines</i> , 2008, 7, 373-381.	4.4	47
22	Cure of Mice with Established Metastatic Friend Leukemia Cell Tumors by a Combined Therapy with Tumor Cells Expressing Both Interferon- γ and Herpes Simplex Thymidine Kinase Followed by Ganciclovir. <i>Human Gene Therapy</i> , 1996, 7, 1-10.	2.7	43
23	Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 121-131.	7.2	43
24	Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. <i>Aids</i> , 2001, 15, 2231-2238.	2.2	41
25	Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. <i>International Journal of Cancer</i> , 1989, 44, 1108-1116.	5.1	37
26	Pyrimethamine Induces Apoptosis of Melanoma Cells via a Caspase and Cathepsin Double-Edged Mechanism. <i>Cancer Research</i> , 2008, 68, 5291-5300.	0.9	37
27	Intratumoral injection of IFN- α dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139.	4.4	36
28	Modulations of glycerophosphorylcholine and phosphorylcholine in Friend erythroleukemia cells upon in vitro-induced erythroid differentiation: a ^31P NMR study. <i>FEBS Letters</i> , 1984, 176, 88-92.	2.8	34
29	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. <i>Cancer Immunology Research</i> , 2018, 6, 658-670.	3.4	34
30	Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. <i>Vaccine</i> , 2006, 24, S56-S57.	3.8	33
31	Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays. <i>BioMed Research International</i> , 2013, 2013, 1-11.	1.9	33
32	Role of interferon regulatory factor 1 in governing T_{reg} depletion, T_{H1} polarization, inflammasome activation and antitumor efficacy of cyclophosphamide. <i>International Journal of Cancer</i> , 2018, 142, 976-987.	5.1	32
33	Transcript profiling of human dendritic cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma. <i>British Journal of Haematology</i> , 2001, 114, 444-457.	2.5	31
34	Nicotinamide inhibits melanoma in vitro and in vivo. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 211.	8.6	30
35	IFN- γ as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical use. <i>Expert Review of Vaccines</i> , 2011, 10, 487-498.	4.4	29
36	Gene expression profiling and functional activity of human dendritic cells induced with IFN- α -2b: implications for cancer immunotherapy. <i>Clinical Cancer Research</i> , 2003, 9, 2022-31.	7.0	27

#	ARTICLE	IF	CITATIONS
37	The added value of type I interferons to cytotoxic treatments of cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 89-97.	7.2	25
38	The Janus face of cyclophosphamide. <i>OncolImmunology</i> , 2013, 2, e25789.	4.6	23
39	IFN- γ and Novel Strategies of Combination Therapy for Cancer. <i>Annals of the New York Academy of Sciences</i> , 2007, 1112, 256-268.	3.8	22
40	U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. <i>Antiviral Research</i> , 1997, 36, 81-90.	4.1	19
41	Strong CD8 ⁺ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. <i>Vaccine</i> , 2011, 29, 3465-3475.	3.8	17
42	TREATMENT OF SEVERE COMBINED IMMUNODEFICIENCY MICE WITH ANTI-MURINE GRANULOCYTE MONOCLONAL ANTIBODY IMPROVES HUMAN LEUKOCYTE XENOTRANSPLANTATION1. <i>Transplantation</i> , 1998, 65, 416-420.	1.0	17
43	Modulation of TCR recognition of MHC class II/peptide by processed remote N- and C-terminal epitope extensions. <i>Human Immunology</i> , 2000, 61, 753-763.	2.4	16
44	Exploiting dendritic cells in the development of cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 1195-1210.	4.4	15
45	Human Lymphoblastoid CD4 ⁺ T Cells Become Permissive to Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 after Passage into Severe Combined Immunodeficient Mice through In Vivo Upregulation of CCR5: In Vivo Dynamics of CD4 ⁺ T-Cell Differentiation in Pathogenesis of AIDS. <i>Journal of Virology</i> , 1998, 72, 10323-10327.	3.4	12
46	Efficient Stimulation of T Cell Responses by Human IFN- γ -induced Dendritic Cells Does Not Require Toll-like Receptor Triggering. <i>Journal of Immunotherapy</i> , 2008, 31, 466-474.	2.4	10
47	Wheat germ agglutinin-binding protein changes in highly malignant Friend leukemia cells metastasizing to the liver. <i>Clinical and Experimental Metastasis</i> , 1988, 6, 347-362.	3.3	9
48	Murine interferon- γ 1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon- γ 1 ² therapy. <i>Cancer Gene Therapy</i> , 1999, 6, 246-253.	4.6	9
49	Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 582744.	4.8	9
50	Alterations of lipid composition in Friend leukemia cell tumors in mice treated with tumor necrosis factor- α . <i>FEBS Letters</i> , 1990, 260, 220-224.	2.8	8
51	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020, 9, 940.	4.1	8
52	Specific Interferon Genes Are Expressed in Individual Cells in the Peritoneum and Bone Marrow of Normal Mice. <i>Journal of Interferon Research</i> , 1992, 12, 27-34.	1.2	7
53	Shifting Gene Expression Profiles During Ex Vivo Culture of Renal Tumor Cells: Implications for Cancer Immunotherapy. <i>Oncology Research</i> , 2003, 14, 133-145.	1.5	7
54	Activation of Glycerophosphocholine Phosphodiesterase in Friend Leukemia Cells Upon In Vitro Induced Erythroid Differentiation. ³¹ P and ¹ H NMR Studies. <i>Israel Journal of Chemistry</i> , 1992, 32, 291-298.	2.3	6

#	ARTICLE	IF	CITATIONS
55	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>Onc Immunology</i> , 2018, 7, e1465163.	4.6	6
56	Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study. <i>Frontiers in Oncology</i> , 2020, 10, 202.	2.8	6
57	Type I interferons induce peripheral T regulatory cell differentiation under tolerogenic conditions. <i>International Immunology</i> , 2021, 33, 59-77.	4.0	6
58	MHV-68 producing mIFN γ 1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68. <i>Vaccine</i> , 2011, 29, 3935-3944.	3.8	5
59	Antibody assay for measles virus: Comparisons of immune adherence haemagglutination, single radial haemolysis, enzyme immunoassay and haemagglutination inhibition. <i>Journal of Virological Methods</i> , 1983, 6, 303-310.	2.1	4
60	Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. <i>Oncotarget</i> , 2016, 7, 59754-59765.	1.8	4
61	In vitro immunization with a recombinant antigen carrying the HIV-1 RT248 Δ 262 determinant inserted at different locations results in altered TCRVB region usage. <i>Human Immunology</i> , 1999, 60, 755-763.	2.4	3
62	Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host. <i>International Journal of Cancer</i> , 1995, 62, 184-190.	5.1	2
63	Administration of different antigenic forms of altered peptide ligands derived from HIV-1 RTase influences their effects on T helper cell activation. <i>Human Immunology</i> , 2003, 64, 1-8.	2.4	2
64	Studies on the expression of H-2 antigens in non-metastatic and highly metastatic Friend erythroleukemia cells: correlation with their vivo behaviour of tumor cells. <i>Clinical and Experimental Metastasis</i> , 1989, 7, 609-625.	3.3	1
65	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 1-3.	7.2	1